Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute (NKI)/Antoni van Leeuwenhoek Hospital in Amsterdam where it had access to the world's largest frozen tumour bank.

Agendia, a US and Netherlands-based personalized medicine company for treating breast cancer spun out off of the Netherlands Cancer Institute, has raised $65m in its series F round from a consortium led by the Debiopharm Group, a Switzerland-based drugs company.

The syndicate was joined by several new international investors including Korys, the Colruyt’s family office, and existing investors, including venture capital firm Gilde Healthcare Partners, family office Van Herk Group, Dutch bank ING Corporate Investments and Breedinvest, the holding…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?